格隆汇9月3日丨百普赛斯(301080.SZ)公布，截至公告披露日，公司通过股份回购专用证券账户以集中 竞价交易方式累计回购股份数量为61.27万股，占公司总股本的0.3650%，最高成交价为54.83元/股，最 低成交价为41.82元/股，成交总金额为2985.04万元(不含交易费用)。本次回购方案实施完毕。 ...

截至本公告披露日，公司回购股份方案已实施完毕。根据《上市公司股份回 购规则》《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相关 规定，现将本次回购实施结果公告如下： 一、回购股份的具体实施情况 证券代码：301080 证券简称：百普赛斯 公告编号：2025-058 北京百普赛斯生物科技股份有限公司 关于股份回购完成暨回购实施结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"或"本公司"）于 2024 年 8 月 29 日召开第二届董事会第八次会议，并于 2024 年 9 月 20 日召开 2024 年第一次临时股东大会审议通过了《关于回购公司股份方案的议案》，同意公司 使用自有资金以集中竞价交易方式回购公司部分已发行的人民币普通股股份，用 于注销并相应减少公司注册资本。本次回购资金总额不低于人民币 2,000 万元（含） 且不超过人民币 4,000 万元（含），回购价格不超过人民币 50.00 元/股（含）， 回购实施期限为自公司股东大会审议通过本次回购股份方案之日起 12 个月内。 具体 ...

Group 1 - The biopharmaceutical sector experienced a decline of 0.64% on September 3, with Sai Sheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] - Notable gainers in the biopharmaceutical sector included Baipu Sais, which rose by 12.10% to a closing price of 65.50, and Yuan Yang Crystal Sea, which increased by 9.14% to 32.95 [1] Group 2 - The net capital outflow from the biopharmaceutical sector was 446 million yuan, while retail investors saw a net inflow of 292 million yuan [3] - The table of individual stock capital flows indicates varying levels of investment activity among different companies within the sector [3]

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., has shown significant growth in its stock performance and business operations, particularly in the fields of recombinant proteins and cell immunotherapy, benefiting from various market trends and developments [1][2][4]. Company Overview - Beijing Baipusais Biotechnology Co., Ltd. was established on July 22, 2010, and went public on October 18, 2021. The company specializes in providing key biological reagent products and technical services, with its main business revenue composition being 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [8]. Financial Performance - For the first half of 2025, the company achieved a revenue of 387 million yuan, representing a year-on-year growth of 29.38%. The net profit attributable to the parent company was 83.8 million yuan, reflecting a year-on-year increase of 47.81% [9]. - As of June 30, 2025, the company had a total market capitalization of 10.994 billion yuan, with a trading volume of 352 million yuan and a turnover rate of 4.46% [1][9]. Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [3]. - The company benefits from a significant overseas revenue share, accounting for 66.46% of its total revenue, which is positively impacted by the depreciation of the Chinese yuan [4]. Product Development and Innovation - The company has developed a range of high-quality recombinant proteins targeting various disease markers and has expanded its product offerings in the CAR-T cell therapy field, including specific antibodies and various assay kits [2]. - The company is actively developing products related to monkeypox virus prevention and treatment, having launched multiple recombinant proteins, antibodies, and assay kits [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 百普赛斯于2024年8月29日召开第二届董事会第八次会议，同年9月20日召开2024年第一次临时股东大 会，审议通过《关于回购公司股份方案的议案》。公司决定使用自有资金，以集中竞价交易方式回购部 分已发行的人民币普通股股份，用于注销并减少公司注册资本。 此次回购资金总额设定在2000万元（含）至4000万元（含）之间，回购价格上限为50.00元/股（含）， 回购实施期限为自股东大会审议通过方案之日起12个月内。相关公告于2024年8月30日、9月20日在巨潮 资讯网披露。 2025年6月24日，公司第二届董事会第十九次会议审议通过《关于调整回购股份价格上限的议案》，将 回购价格上限提升至80.00元/股（含），该调整自当日生效。2024年年度权益分派实施后，因相关规 定，自2025年7月11日除权除息日起，回购股份价格上限调整为56.91元/股（含）。 截至2025年8月31日，公司通过股份回购专用证券账户，以集中竞价交易方式回购股份40.01万股，占公 司总股本的0.33%，最高成交价为50.00元/股，最低成交价为49.98元/股，支付的总金额为1999. ...

证券日报网讯9月2日晚间，百普赛斯（301080）发布公告称，截至2025年8月31日，公司通过股份回购 专用证券账户以集中竞价交易方式累计回购股份数量为612，700股，占公司总股本的0.3650%。 ...

Group 1 - The company Baipusais (SZ 301080) announced on September 2 that it has repurchased approximately 610,000 shares, accounting for 0.365% of its total share capital, with a total transaction amount of about 29.85 million yuan [1] - The highest transaction price for the repurchased shares was 54.83 yuan per share, while the lowest was 41.82 yuan per share [1] - For the fiscal year 2024, the company's revenue composition is as follows: 98.13% from research and experimental development, and 1.87% from other businesses [1] Group 2 - As of the report date, Baipusais has a market capitalization of 9.8 billion yuan [2]

格隆汇9月2日丨百普赛斯(301080.SZ)公布，截至2025年8月31日，公司通过股份回购专用证券账户以集 中竞价交易方式累计回购股份数量为612,700股，占公司总股本的0.3650%，最高成交价为54.83元/股， 最低成交价为41.82元/股，成交总金额为2985.04万元(不含交易费用)。 ...

北京百普赛斯生物科技股份有限公司（以下简称"公司"或"本公司"）于 2024 年 8 月 29 日召开第二届董事会第八次会议，并于 2024 年 9 月 20 日召开 2024 年第一次临时股东大会审议通过了《关于回购公司股份方案的议案》，同意公司 使用自有资金以集中竞价交易方式回购公司部分已发行的人民币普通股股份，用 于注销并相应减少公司注册资本。本次回购资金总额不低于人民币 2,000 万元（含） 且不超过人民币 4,000 万元（含），回购价格不超过人民币 50.00 元/股（含）， 回购实施期限为自公司股东大会审议通过本次回购股份方案之日起 12 个月内。 具体内容详见公司分别于 2024 年 8 月 30 日、2024 年 9 月 20 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编号： 2024-026）和《回购报告书》（公告编号：2024-030）。 公司于 2025 年 6 月 24 日召开第二届董事会第十九次会议，审议通过了《关 于调整回购股份价格上限的议案》，同意公司将回购价格上限调整为 80.00 元/ 股（含）。调整后的回购股份价格上 ...

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is experiencing growth in its business driven by its innovative biotechnological products and services, particularly in recombinant proteins and CAR-T cell therapies, while also benefiting from the depreciation of the RMB [2][4]. Group 1: Business Performance - The company reported a revenue of 387 million yuan for the first half of 2025, representing a year-on-year growth of 29.38% [9]. - The net profit attributable to the parent company for the same period was 83.8 million yuan, showing a year-on-year increase of 47.81% [9]. - The company's overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Product Development - The company has developed a range of high-quality recombinant proteins targeting various diseases, which supports the research and production of biopharmaceuticals [2]. - It has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product offerings in cell and gene therapy [2]. - The company is actively developing products related to monkeypox virus, including recombinant proteins and antibodies, to support vaccine and therapeutic drug development [2]. Group 3: Industry Recognition - The company has been recognized as a "specialized and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and possessing strong innovation capabilities [3]. - It is positioned within the pharmaceutical and biotechnology industry, specifically in the bioproducts sector, and is involved in various concepts such as biomedicine and monkeypox [9]. Group 4: Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 10.85% to 11,700, with an average of 7,711 shares held per shareholder, a decrease of 9.79% [9]. - The stock price has shown some upward movement, with a recent increase of 2.08% and a total market capitalization of 10.042 billion yuan [1].